News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scheer Partners, Inc. Represents Immunomic Therapeutics in New Lease for Rockville Lab Space



10/12/2012 11:06:27 AM

Rockville, MD (October 12, 2012) – A Pennsylvania-based biotechnology company has opened an R&D facility in Rockville, the result of a transaction completed by two Scheer Partners executives.

The leading provider of fully integrated commercial real estate services for the health science industry in the Washington and Baltimore metropolitan areas, Scheer Partners announces today that it has negotiated on behalf of Immunomic Therapeutics in a 3,500-square-foot lease of laboratory space at 15010 Broschart Road, which is owned by Pasadena, Calif.-based Alexandria Real Estate Equities.

In this new multi-year lease, Scheer Partners Senior Vice President Henry Bernstein and Vice President Matt Brady represented Immunomic Therapeutics, a clinical-stage biotech company headquartered in Lancaster, Pa.

Previously, Immunomic Therapeutics occupied a small amount of temporary lab space in Montgomery County before recently settling into its new Rockville facility on Broschart Road.

The privately held company is developing next-generation vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) technology, which emerged from $20 million of National Institutes of Health-funded research conducted by Dr. Tom August at the Johns Hopkins University School of Medicine.

Immunomic Therapeutics has the exclusive worldwide license to the LAMP technology patent estate and is working to commercialize ground-breaking vaccines, with an initial concentration in allergy, cancer and infectious diseases.

The company’s vaccine platform significantly increases the effectiveness of the immune system’s response to nucleic-acid vaccines, while simplifying overall vaccine design and delivery. This, in turn, yields safer, more cost-efffective human and animal therapies.

Says Bernstein: “We’re extremely pleased to have secured new R&D space in Rockville for Immunomic Therapeutics. Led by long-time biotech entrepreneur Bill Hearl, the company’s founder and CEO, Immunomic Therapeutics is an extremely promising biotech firm focused on becoming the leading commercial DNA vaccine company.”

For more information on Immunomic Therapeutics, please visit its Web site at www.immunomix.com.

About Scheer Partners:

Founded in 1991, Scheer Partners is a full-service commercial real estate firm headquartered in Rockville, Md. With a focus on the greater Washington and Baltimore regions, Scheer Partners’ fully integrated services include tenant and landlord representation; strategic planning consulting; facilities and construction management; and investment sales, acquisitions and development. While the firm works with clients across all industry types, Scheer Partners is the recognized leader serving the health-care market, with more than 500 successful projects in this sector. Scheer Partners is the operations manager for Montgomery County's technology incubator program, which has more than 160 tenants, and is co-manager of the Greater Washington Life Sciences Fund. The company’s Web site is www.scheerpartners.com.

For more information, please contact:

Neil Adler of D*MNGOOD®

202-683-8975 (office)

410-499-5004 (cell)

neil.adler@dmngood.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES